Linguamatics and RealHealthData aim to help pharmaceutical and biotechnology company researchers understand the impact of their therapies on patients outside of clinical trials. Under the partnership, Linguamatics will use its NLP technology on RealHealthData’s database of provider narratives to inform evidence about drug use and adverse events.
The use data from patients’ medical records will help to support all phases of drug development, including post-market research, according to Linguamatics and RealHealthData. Researchers who query the data will also be able to identify whether impacted patients had previous comorbidities, complications or co-medications, among other medical considerations.
More articles on health IT:
Report: 5 best, worst states for EHR adoption
Philips opens ‘innovation center’ in Pittsburgh
Meditech revenue dips 3% in Q2: 4 things to know
